explore -WSS

explore

author：knowledge 2025-10-02 06:02:22 - browse：7

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： STAT Summit: The economic case for universal basic health care

focus

leisure time

WSS

Boston hospital trains restaurant workers on naloxone for overdoses

Boston hospital trains restaurant workers on naloxone for overdoses

Readout LOUD podcast: Live from the 2023 STAT Summit

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

ADCs take center stage as promising cancer treatments

STAT series 'Denied by AI' wins major journalism prizes

explore

explore

hotspot

Drug repurposing or repositioning? The language matters

Lilly’s weekly insulin works as well as daily products, new studies show

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

STAT Summit: Meghan O’Rourke on making chronic illness visible

The high cost of giving birth even with insurance

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Summit: The economic case for universal basic health care

Drug repurposing or repositioning? The language matters

ALS treatment from Biogen, Ionis fails in study

Wikipedia

STAT reporters are Pulitzer Prize finalists for investigative reporting

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

STAT Summit: Meghan O’Rourke on making chronic illness visible

Cherokee Nation medical school graduates its first class

Cassava Sciences’ Alzheimer’s clinical trials should be halted

leisure time

focus

leisure time

explore